VERISIGN INC/CA — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that VERISIGN INC/CA filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.66B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.56B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $1.49B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $1.42B | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $1.33B | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $1.27B | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.23B | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $1.21B | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $1.17B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $1.14B | Feb 15, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $320.03M | Feb 28, 2013 |
| FY2012 | Dec 31, 2011 | $142.89M | Feb 28, 2013 |
| FY2012 | Dec 31, 2010 | $830.97M | Feb 28, 2013 |
| FY2011 | Dec 31, 2009 | $245.55M | Feb 24, 2012 |
| FY2010 | Dec 31, 2008 | ($374.25M) | Feb 24, 2011 |
| FY2009 | Dec 31, 2007 | ($150.35M) | Feb 26, 2010 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.12B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $1.00B | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $943.10M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $866.80M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $824.20M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $806.13M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $767.39M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $707.72M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $686.57M | Feb 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $103.60M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $96.70M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $91.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $85.70M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $80.50M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $74.70M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $60.81M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $57.88M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $52.34M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $59.10M | Feb 15, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $235.70M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $211.10M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $204.20M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $195.40M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $188.40M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $186.00M | Feb 17, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.09B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $902.60M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $853.80M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $831.10M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $807.20M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $730.20M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $753.89M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $697.77M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $702.76M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $693.01M | Feb 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.80M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $28.10M | Feb 5, 2026 |
| FY2025 | Dec 31, 2023 | $45.80M | Feb 5, 2026 |
| FY2024 | Dec 31, 2022 | $27.40M | Feb 13, 2025 |
| FY2023 | Dec 31, 2021 | $53.00M | Feb 15, 2024 |
| FY2022 | Dec 31, 2020 | $43.40M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $40.32M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $37.01M | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | $49.50M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $26.57M | Feb 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.33B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $1.41B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $1.75B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $1.73B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $1.98B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.77B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.85B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.91B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $2.94B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $2.33B | Feb 16, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.48B | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $3.36B | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $3.33B | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $3.30B | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $3.24B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $3.16B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $3.34B | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $3.30B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $4.20B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $3.54B | Feb 16, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($2.15B) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($1.96B) | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | ($1.58B) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($1.56B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($1.26B) | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | ($1.39B) | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | ($1.49B) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($1.39B) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($1.26B) | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | ($1.20B) | Feb 16, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.50M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $52.50M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $52.50M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $52.50M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $52.50M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $52.53M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $52.53M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $52.53M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $52.53M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $52.53M | Feb 16, 2018 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($11.78B) | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | ($12.60B) | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | ($13.39B) | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | ($14.20B) | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | ($14.88B) | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | ($15.66B) | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | ($16.48B) | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | ($17.09B) | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | ($17.69B) | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | ($18.18B) | Feb 16, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $307.90M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | $206.70M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | $240.10M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | $373.60M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | $223.50M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $401.19M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $508.20M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | $357.42M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $465.85M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $231.95M | Feb 16, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2013 | Dec 31, 2013 | $0 | Feb 21, 2014 |
| FY2012 | Dec 31, 2012 | $100.00M | Feb 28, 2013 |
| FY2012 | Dec 31, 2011 | $100.00M | Feb 28, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 6 | Feb 17, 2023 |
| FY2022 | Dec 31, 2021 | 7 | Feb 17, 2023 |
| FY2022 | Dec 31, 2020 | 7 | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | 5 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 4 | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | 4 | Feb 15, 2019 |
| FY2017 | Dec 31, 2015 | 3 | Feb 16, 2018 |
| FY2016 | Dec 31, 2014 | 2 | Feb 17, 2017 |
| FY2015 | Dec 31, 2013 | 3 | Feb 19, 2016 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | 6 | Feb 17, 2023 |
| FY2022 | Dec 31, 2021 | 7 | Feb 17, 2023 |
| FY2022 | Dec 31, 2020 | 7 | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | 5 | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | 4 | Feb 19, 2021 |
| FY2019 | Dec 31, 2017 | 3 | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | 3 | Feb 15, 2019 |
| FY2017 | Dec 31, 2015 | 2 | Feb 16, 2018 |
| FY2016 | Dec 31, 2014 | 2 | Feb 17, 2017 |
| FY2015 | Dec 31, 2013 | 3 | Feb 19, 2016 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 91.90M | Feb 5, 2026 |
| FY2025 | Dec 31, 2024 | 95.00M | Feb 5, 2026 |
| FY2024 | Dec 31, 2023 | 101.30M | Feb 13, 2025 |
| FY2023 | Dec 31, 2022 | 105.30M | Feb 15, 2024 |
| FY2022 | Dec 31, 2021 | 110.50M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | 113.47M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | 116.72M | Feb 19, 2021 |
| FY2019 | Dec 31, 2018 | 120.04M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | 97.59M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | 103.09M | Feb 16, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Dec 31, 2011 | $463.50M | Feb 24, 2012 |
| FY2010 | Dec 31, 2010 | $518.22M | Feb 24, 2011 |